A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

Stopped The Sponsor decided to discontinue the development of RO7565020 and as a result the BP44118 study was terminated.

Conditions

• Chronic Hepatitis B

Interventions

• DRUG: RO7565020
• OTHER: Placebo
• DRUG: Nucleos(t)ide analogue (NUC) treatment

Sponsor

Hoffmann-La Roche